摘要:
The present invention provides a process for preparing a sugar chain asparagine derivative. According to the process, various isolated sugar chain asparagine derivatives useful in the field of the development of pharmaceuticals and the like can be conveniently obtained in a large amount as compared to that of the prior art. The present invention also provides a process for preparing a sugar chain asparagine and a process for preparing a sugar chain via a step for preparing a sugar chain asparagine derivative. The present invention further provides a novel sugar chain asparagine derivative, a sugar chain asparagine and a sugar chain.
摘要:
Pro-drugs of all non-steroidal anti-inf lammatories with free acid function derivatized with an ester group, which have the general structural formula given below (I) where A is: aspirin, diflunisal, benorylate, ibufenac, diclofenac, indomethacin, sulindac, ketorolac, ibuprofen, naproxen, ketoprofen, fenoprofen, flurbiprofen, mefenamic acid, meclof enamic acid, flufenamic acid, niflumic acid, and where in the ester group R can be a sugar (amongst which aldose, or ketose pentose, or esose selected from a group of D- and L- enantioiuers of ribose, glucose, galactose, mannose, arabinose, xilose, allose, altrose, gulose, idose and talose and substituted derivatives thereof, such as glucosamine, galactosamine, N -acetyl glucosamine, N -acetyl galactosamine, N -acetyl ribosamine), a disaccharide, a trisaccharide or an oligosaccharide.
摘要:
Methods of inhibiting the cytokine or biological activity of Macrophage Migration Inhibitory Factor (MIF) comprising contacting MIF with a compound of formula (I) as defined herein, is provided. The invention also relates to methods of treating diseases or conditions where MIF cytokine or biological activity is implicated comprising administration of compounds of formula (I), either alone or as part of a combination therapy. Novel heterocyclic compounds are also provided for.
摘要:
Where Y, R 1 -R 8 and R 101 -R 108 are as defined in the specification. Compounds of formula (II) and methods of inhibiting the cytokine or biological activity of Macrophage Migrating Inhibitory Factor (MIF) comprising contacting MIF with a compound of formula (I) are provided. The invention also relates to methods of treating diseases or conditions where MIF cytokine or biological activity is implicated comprising administration of compounds of formula (1), either alone or as part of a combination therapy.
摘要:
Methods of inhibiting the cytokine or biological activity of Macrophage Migration Inhibitory Factor (MIF) comprising contacting MIF with a compound of formula (I) as defined herein, is provided. The invention also relates to methods of treating diseases or conditions where MIF cytokine or biological activity is implicated comprising administration of compounds of formula (I), either alone or as part of a combination therapy. Novel heterocyclic compounds are also provided for.
摘要:
Methods of inhibiting the cytokine or biological activity of Macrophage Migration Inhibitory Factor (MIF) comprising contacting MIF with a compound of formula (I) as defined herein, is provided. The invention also relates to methods of treating diseases or conditions where MIF cytokine or biological activity is implicated comprising administration of compounds of formula (I), either alone or as part of a combination therapy. Novel heterocyclic compounds are also provided for.
摘要:
The invention is in the field of biologically active compounds such as taxol-2'-adipate derivatives, derivatives of bergenin and erythromycin derivatives. Taxol-2'-adipate derivatives have anti-cancer activity analogous to taxol. Bergenin derivatives have angiotensin converting enzyme inhibiting activity, and are therefore useful in the treatment of hypertension. Erythromycin derivatives are useful as antibiotics.
摘要:
Die vorliegende Erfindung betrifft neue Schwefelsäureester von Aminozuckern der allgemeinen Formel Ia, Ib, Ic worin
B niederes Alkylen oder ein gegebenenfalls substituiertes aromatisches Ringsystem; G 1 , G 2 und G 3 unabhängig voneinander je einen Rest eines Glycopyranosids, einer Glycopyranose oder eines Derivates davon, wobei mindestens eine Hydroxygruppe der Reste G 1 , G 2 oder G 3 mit Schwefelsäure verestert ist, bedeuten und pharmazeutisch anwendbare Salze davon.
Die Verbindungen eignen sich als therapeutische Wirkstoffe zur Behandlung von Krankheiten, die durch exzessive oder destruktive Proliferation von glatten Muskelzellen gekennzeichnet ist.
摘要:
L'invention concerne des Tris acétyl-2˝,3˝,4′ éthylidène-4˝,6˝ β-D-glucopyranosides, leur préparation et leur utilisation pour la préparation d'éthylidène β-D-glucopyranoside de déméthyl-4′ épipodophyllotoxine. Les composés de l'invention répondent à la formule 1 Leur procédé de préparation comporte les étapes suivantes : acylation d'un dérivé glycosylé acylation d'une aglycone couplage du dérivé glycosylé acylé et de l'aglycone acylée, en présence d'un acide de Lewis, l'acylation étant effectuée à l'aide d'un chlorure d'acide, éventuellement identique pour les deux étapes d'acylation, dans lequel le carbone en α de la fonction carbonyle porte au moins un hétéroatome choisi parmi O et S.
摘要:
Compounds having anti-inflammatory and other activities. The compounds are derived from diterpenes, indol alkaloids, polyacetates, diaminobenzyl alcohols, diacylglycerol and bryostatins.